Clinical Characteristics of Monomorphic Post-transplant Lymphoproliferative Disorders

다국어 초록 (Multilingual Abstract)

Post-transplant lymphoproliferative disorders (PTLD) are a heterogeneous group of lymphoproliferative disorders associated with immunosuppression and Epstein-Barr virus infection. PTLD is classified into three major categories: early lesions,polymorphic PTLD, and monomorphic PTLD. The majority of monomorphic PTLD cases are non-Hodgkin’s lymphoma of B-cell origin. This retrospective study was conducted to investigate the incidence, clinical manifestation, treatment, and outcomes of monomorphic PTLD among 5,817 recipients of solid organ or allogeneic hematopoietic stem cell transplantation from five institutions. Fourteen patients with monomorphic PTLD were identified (male:female 11:3; median age 42.6 yr, range 24-60). The overall incidence rate was 0.24%. The most common disease type was diffuse large B cell lymphoma (n=7). The median time between the transplant and diagnosis of PTLD was 85.8 months. However, all cases of PTLD after allogeneic hematopoietic stem cell transplantation occurred within 1 yr after transplantation. Ten of the 14 patients had EBV-positive tumor. Fourteen patients received combination systemic chemotherapy and four patients were treated with radiation therapy. Ten patients achieved a complete response (CR) and two patients a partial response (PR). The median follow-up period for surviving patients was 36.6 months. Nine patients remain alive (eight CR, one PR). Nine of 11 solid organ transplantations preserved graft function. The present study indicates a lower incidence rate and a longer median time before the development of PTLD than those of previous reports.
Careful monitoring was needed after allogeneic hematopoietic stem cell transplantation for PTLD.

참고문헌 (Reference)

1 Buadi FK, "Treatment and outcomes of post-transplant lymphoproliferative disease: a single institution study" 82 : 208-214, 2007

2 Harris NL, "The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997" 36 : 69-86, 2000

3 Leblond V, "Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?" 16 : 2052-2059, 1998

4 Lee JJ, "Posttransplant lymphoproliferative disorders in kidney transplant patients: report from a single-center over 25 years" 22 : 226-231, 2008

5 Swerdlow SH, "Post-transplant lymphoproliferative disorders. In: The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues" IARC 343-349, 2008

6 LaCasce AS, "Post-transplant lymphoproliferative disorders" 11 : 674-680, 2006

7 Hou HA, "Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years’ experience in a single institute" 43 : 315-321, 2009

8 Nelson BP, "Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?" 24 : 375-385, 2000

9 Mee Soo Chung, "Epstein-Barr Virus in Human Malignancy: A Special Reference to Epstein-Barr Virus Associated Gastric Carcinoma" 대한암학회 37 (37): 257-267, 2005

10 Savoie A, "Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease" 83 : 2715-2722, 1994

11 Ghobrial IM, "Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases?" 79 : 244-247, 2005